Patients with metastatic melanoma often have defects in the percentage and function of peripheral blood NK cells, which are involved in the non-specific innate antitumor immune response, and T cells, which participate in the specific acquired antitumor immune response. The aim of this study was to investigate in more detail not only the percentage but also the activation status and function of NK and T cells in patients with metastatic melanoma prior to therapy.
Methods
The percentage of peripheral blood CD56+ NK cells, CD3+ T cells and their CD4+ and CD8+ subsets, as well as the expression of the activation antigens CD69, CD38 and HLA-DR were analyzed by flow cytometry. The functional capacity of NK cells was evaluated by the 51-chromium release cytotoxicity assay, while the proliferative activity of T cells was estimated by the lymphocyte transformation test to mitogen phytohemagglutinin.
Results
The results obtained in this study have revealed a new aspect of NK and T cell dysfunction that is not, as commonly reported, associated with a decrease in their percentage. Moreover, a significant number of the investigated patients had a higher percentage of NK cells that did not lead to improved NK ceil cytotoxicity as a result of the detected defect in the NK cell perforin-mediated cytotoxic mechanism of tumor cell lysis. The impaired proliferative response of T cells was associated with a decreased expression of the activation antigen HLA-DR.
Conclusion
The novel finding in this study of melanoma patients with metastatic disease is the impaired perforin-depen-dent NK cell cytotoxic mechanism, which was recently shown to be primarily responsible for preventing metastasis. Another interesting finding was the generally hyporeactive status of T cells, possibly resulting from persistent antigenic stimulation. The observed dysfunction of NK and T cells in patients with metastatic melanoma prior to therapy point to the need to supplement chemotherapy with appropriate immunotherapeutic agents in order to overcome the immunosuppression associated with advanced malignancy.
CasselD., FormanJ.: Two roles of CD4 cells in the control of generation of cytotoxic T lymphocytes.J Immunol, 146: 3–10, 1991.
4.
HungK., HayashiR., Lafond-WalkerA., LowensteinC., Par-dollD., LevitskyH.: The central role of CD4+ T cells in the antitumor immune response.J Exp Med, 188: 2357–2368, 1998.
5.
CavalcantiM., JewettA., BonavidaB.: Irreversible cancer cell-induced functional anergy and apoptosis in resting and activated NK cells.Int J Oncol, 14: 361–366, 1999.
6.
MarrackP., KapplerJ., MitchellT.: Type I interferons keep activated T cells alive.J Exp Med, 189: 521–530, 1999.
7.
SmythM.J., KellyJ.M., BaxterA.G., KornerH., SedgwickJ.D.: An essential role for tumor necrosis factor in NK cell-mediated tumor rejection in the peritoneum.J Exp Med, 188: 1611–1619, 1998.
8.
SmythM.J., ThiaK.Y., CretneyE., KellyJ.M., SnookM.B., ForbesC.A., ScalzoA.A.: Perforin is a major contributor to NK cell control of tumor metastasis.J Immunol, 162: 6658–6662, 1999.
9.
SmythM.J., KershawM.H., TrapaniJ.A.: Xenospecific cytotoxic T lymphocytes: potent lysis in vitro and in vivo.Transplantation, 63: 1171–1178, 1997.
10.
Van den BroekM.F., KagiD., OssendorpF., ToesR., VamvakasS., LutzW.K., MeliefC.J.M., ZinkernagelM., HengartnerH.: Decreased tumor surveillance in perforin-deficient mice.J Exp Med, 184: 1781–1790, 1996
11.
ContiL., AristaM.C., CallopoliA., FilippoF.D., FranceschiL.D., MacaleE., FrancavillaV., GirelliG., VitelliG., GandolfoG.M., CavaliereR.: Flow cytometry evaluation of lymphocyte subsets in non-treated neoplastic patients.J Clin Exp Cancer Res, 15: 257–264, 1996.
12.
EisenthalA., SkornickY., RonI., ZakuthV., ChaitchikS.: Phe-notypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.Cancer Immunol Immunother, 37: 367–372, 1993.
13.
GabrilovacJ.: [Natural killer (NK) cell activity in the peripheral blood of patients with malignant diseases: melanoma, carcinoma, chronic and acute lymphatic leukemia].Lijec Vjesn, 107: 323–326, 1985.
14.
MullerC., PehambergerH., BinderM., ZielinskiC.C.: Defective interferon-augmented natural killer cell activity in patients with metastatic malignant melanoma.J Cancer Res Clin Oncol, 115: 393–396, 1989.
15.
JacksonA., WarnerN.: Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes.In: Manual of clinical laboratory immunology, RoseN., FriedmanH., FaheyJ. (Eds), 226–235, American Society for Microbiology, Washington DC, 1986.
16.
BrownR.L., OrtaldoJ.R., GriffithR.L.: The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium.J Immunol Methods, 81: 207–214, 1985.
17.
YaoX.L., JenkinsE.C., WisniewskiH.M.: Effect of aluminium chloride on mitogenesis, mitosis and cell cycle in human short-term whole blood cultures: lower concentrations enhance mitosis.J Cell Biochem, 54: 473–477, 1994.
18.
SibbitW.L., BankhurstA.D., JumonvilleA.J., SaikiJ.H., SaiersJ.H., DoberneckJ.C.: Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma.Cancer Res, 44: 852–856, 1984.
19.
deShazoR.D., MoulderP.V., BozelkaB., ChapmanY.: Diminished natural killer-cell activity of interstitial pulmonary cell populations from patients with carcinoma of the lung.Chest, 91: 26–28, 1987.
20.
KonjevicG., JurisicV., BanicevicB., SpuzicI.: The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease.Br J Haematol, 104: 144–151, 1999.
21.
MasseriniC., VillaM.L., RoviniD., ClericiE.: [Natural killer activity in patients with malignant melanoma].Boll Ist Sieroter Milan, 60: 307–315, 1981.
22.
KonjevicG., SpuzicI.: Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer.Neoplasma, 40: 81–85, 1993.
23.
KonjevicG., JovicV., RadulovicS., JelićS., DzodićR., SpuzićI.: Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.Neoplasma2001 (in press).
24.
SteinhauerE.H., DoyleA.T., ReedJ., KadishA.S.: Defective natural cytotoxicity in patients with cancer: normal number of effector cells but decreased recycling capacity in patients with advanced disease.J Immunol, 129: 2255–2259, 1982.
25.
SimmsP.E., EllisT.M.: Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly-and oligoclonal lymphocyte activation.Clin Diagn Lab Immunol3: 301–304, 1996.
26.
KodamaT., TakedaK., ShimozatoO.: Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12.Eur J Immunol, 29: 1390–1396, 1999.
27.
OshimiY., OdaS., HondaY., NagataS., MiyazakiS.: Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells.J Immunol, 157: 2909–2915, 1996.
28.
DavisJ.E., SmythM.J., TrapaniJ.A.: Granzyme A and B-defi-cient killer lymphocytes are defective in eliciting DNA fragmentation but retain potent in vivo antitumor capacity.Eur J Immunol, 31: 39–47, 2001.
29.
van den BroekM.F., KagiD., ZinkernagelR.M., HengartnerH.: Perforin dependence of natural killer cell-mediated tumor control in vivo.Eur J Immunol, 25: 3514, 1995.
30.
JurisicV., KonjevicG., BanicevicB., DjurisicB., SpuzicI.: Different alteration in lactate dehydrogenase activity and profile of peripheral blood mononuclear cells in Hodgkin's and non-Hodgkin's lymphomas.Eur J Haematol, 200: 259–266, 2000.
31.
KagiD., LedermannB., BurkiK., SeilerP., OdermattB., OlsenK.J., PodackE.R., ZinkernagelR.M., HengartnerH.: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice.Nature, 369: 31–37, 1994
32.
HigginsC.F.: Membrane permeability transporters and channels: from disease to structure and back.Curr Opin Biol, 11: 495–499, 1999.
33.
JewettA., CavalcantiM., BonavidaB.: Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells.J Immunol, 159: 4815–4822, 1997.
34.
JurisicV., SpuzicI., KonjevicG.: A comparison of the NK cell cytotoxicity with effects of TNF-α against K-562 cells, determined by LDH release assay.Cancer Lett, 138: 67–72, 1999.
35.
KadishA.S., DoyleA.T., SteinhauerE.H., GhosseinN.A.: Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease.J Immunol, 127: 1817–1822, 1981.
36.
KishiA., OhmoriM., TomitaS., NimanM., UnoK., TanigawaM., SetoguchiJ., NittaH., IkedaT., KishidaT., FujitaS.: Pheno-typic and functional analyses of natural killer cells: impaired NK activity partly due to the CD56+ cell dysfunction in cancer patients.Int J Immunotherapy, 15: 1–12, 1999.
37.
WhitesideT.L.: Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects.Adv Exp Med Biol, 451: 167–171, 1998.
38.
AsoH., TamuraK., YoshieO., NakamuraT., KikuchiS., IshidaN.: Impaired NK response of cancer patients to IFN-a but not to IL-2: correlation with serum immunosuppressive acidic protein (IAP) and role of suppressor macrophage.Microbiol Immunol, 36: 1087–1097, 1992.
TestiR., D'AmbrosioD., De MariaR., SantoniA.: The CD69 receptor: multipurpose cell surface trigger for hematopoietic cells.Immunol Today, 15: 479–483, 1994.
41.
BorregoF., RobertsonM.J., RitzJ., PenaJ., SolanaR.: CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor.J Immunol, 97: 159–165, 1999.
42.
HaynieG.D., ShenT.T., GragoudasE.S., YoungL.H.: Flow cytometry analysis of peripheral blood lymphocytes in patients with choroidal melanoma.Am J Ophthalmol, 124: 357–376, 1997.
43.
KaszubowskiP.A., HusbyG., TungK.S., WilliamsRCJr.: T-lymphocyte subpopulations in peripheral blood and tissues of cancer patients.Cancer Res, 40: 4648–4657, 1980.
44.
ChouaibS., Asselin-PaturelC., Mami-ChouaibF., CaignardA., BlayJ.: The host-tumor immune conflict: from immunosuppression to resistance and destruction.Immunol Today, 18: 493–497, 1997.
45.
PardouxC., MaX., GobertS., PellegriniS., MayeuxP., GayF., TrinchieriG., ChouaibS.: Downregulation of interleukin-12 (IL-12) responsiveness in human T cells by transforming growth factor-beta: relationship with IL-12 signaling.Blood, 93: 1448–1455, 1999.
46.
Asselin-PaturelC., EchchakirH., CarayolG., GayF., OpolonP., GrunenwaldD., ChouaibS., Mami-ChouaibF.: Quantitative analysis of Thl, Th2 and TGF-betal cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients.Int J Cancer, 77: 7–12, 1998.
47.
RothM.D., GolubS.H.: Human pulmonary macrophages utilize prostaglandins and transforming growth factor beta 1 to suppress lymphocyte activation.J Leukoc Biol, 53: 366–371, 1993.
48.
ZeaA., CurtiB., LongoD., AlvordW., StroblS., MizoguchiH., CreekmoreS., O'SheaJ., PowersG., UrbaW., OchoaA.: Alterations in T cell receptor and signal transduction molecules in melanoma patients.Clin Cancer Res, 1: 1327–1335, 1995.
49.
HealyC.G., SimonsJ.W., CarducciM.A., DeWeeseT.L., BartkowskiM., TongK.P., and BoltonW.E.: Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer.Cytometry, 32: 109–119, 1998.
50.
GotoS., SatoM., KanekoR., ItohM., ShoshichiS., TakeuchiS.: Analysis of Thl and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients.Cancer Immunol Immunother, 48: 435–444, 1999.
